NCT00088101View on ClinicalTrials.gov

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

December 31, 2004

Conditions

Hematological MalignanciesLeukemiaLymphomaMetastatic or Unresectable Solid Tumors

Interventions

DRUG

STA-5312

Trial Locations (8)

28203

Carolinas HealthCare System, Charlotte

32207

Baptist Cancer Institute, Jacksonville

37203

The Sarah Cannon Cancer Center, Nashville

38120

The West Clinic, Memphis

60637

University of Chicago, Chicago

91767

Wilshire Oncology Medical Group, Pomona

02111

Tufts New England Medical Center, Boston

Unknown

Newark Beth Israel Medical Center, Newark

All Listed Sponsors

lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT00088101 - STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors | Biotech Hunter | Biotech Hunter